Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02187523
Diuretic Comparison Project
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 20723
- Registration Number
- NCT02185417
- Locations
- 🇺🇸
Maine VA Medical Center, Augusta, ME, Togus, Maine, United States
🇺🇸VA Southern Oregon Rehabilitation Center and Clinics, White City, OR, White City, Oregon, United States
🇺🇸New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 489
- Registration Number
- NCT02177422
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02176512
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: Medium dose of Micardis®Drug: Low dose of Micardis®Drug: High dose of Micardis®
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1039
- Registration Number
- NCT02175355
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 363
- Registration Number
- NCT02172586
Chlorthalidone and HCTZ Impacts on Platelet Activation
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 30
- Registration Number
- NCT02100462
- Locations
- 🇺🇸
Creighton University, Omaha, Nebraska, United States
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
- Conditions
- Grade I or II Essential Hypertension
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 353
- Registration Number
- NCT02072330
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 DiabetesHypertension
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Tulane University School of Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT02046395
- Locations
- 🇺🇸
Tulane University Health Sciences Center, New Orleans, Louisiana, United States
Vascular Dysfunction in Human Obesity Hypertension
- Conditions
- ObesityPrehypertensionHypertension
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Gary L. Pierce
- Target Recruit Count
- 33
- Registration Number
- NCT01983462
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.